Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neuroblastoma × Tissue Banks × CNS × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neuroblastoma 1 Nervous System Neoplasms 1 Central Nervous System Neoplasms 1 Central Nervous System Diseases 1 Brain Neoplasms 1 Brain Diseases 1

Interventions

Cyclophosphamide 87 Etoposide 49 Carboplatin 42 Vincristine 40 Isotretinoin 40 Temozolomide 39 Topotecan 38 Melphalan 38 Irinotecan 38 Filgrastim 38 Doxorubicin 36 3-Iodobenzylguanidine 32 Cisplatin 28 Granulocyte Colony-Stimulating Factor 27 sargramostim 26 Peripheral Blood Stem Cell Transplantation 26 dinutuximab 25 Radiotherapy 24 Granulocyte-Macrophage Colony-Stimulating Factor 24 Busulfan 20 Magnetic Resonance Spectroscopy 17 fludarabine 16 aldesleukin 16 Interleukin-2 15 naxitamab 14 humanized 3F8 anti-GD2 monoclonal antibody 14 Thiotepa 13 fludarabine phosphate 12 etoposide phosphate 12 Biopsy 12

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04239040 2025-03-19

GVAX Plus Checkpoint Blockade in Neuroblastoma

Dana-Farber Cancer Institute

Phase 1 Terminated

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡